6 Apr 2018 13:03
Mereo BioPharma Group plc
("Mereo" or the "Company" or the "Group")
Result of General Meeting
London, April 6, 2018 - Mereo BioPharma Group plc (AIM: MPH), a multi-asset biopharmaceutical company focused on the acquisition, development and commercialisation of innovative therapies that aim to improve outcomes for patients with rare and specialty diseases, announces that the resolution proposed at the Company's General Meeting held today was duly passed.
For Further Enquiries:
Mereo BioPharma Group plc | +44 (0)333 023 7319 |
Denise Scots-Knight, Chief Executive Officer | |
Richard Jones, Chief Financial Officer | |
Nominated Adviser and Joint Broker Cantor Fitzgerald Europe | +44 (0)20 7894 7000 |
Phil Davies | |
Will Goode | |
Joint Broker RBC Capital Markets | +44 (0)20 7653 4000 |
Rupert Walford | |
Laura White | |
UK Public Relations Advisor to Mereo Biopharma FTI Consulting | +44 (0)20 3727 1000 |
Ben Atwell | |
Simon Conway | |
Brett Pollard | |
US Public Relations Advisor to Mereo Biopharma Burns McClellan | +01 (0) 212 213 0006 |
Lisa Burns | |
Steven Klass |
About Mereo
Mereo is a multi-asset biopharmaceutical company focused on the acquisition, development and commercialization of innovative therapeutics that aim to improve outcomes for patients with rare and specialty diseases. The portfolio consists of four clinical-stage product candidates, each of which were acquired from large pharmaceutical companies: BPS-804 for the treatment of osteogenesis imperfecta; AZD-9668 for the treatment of severe alpha-1 antitrypsin deficiency; BCT-197 for the treatment of acute exacerbations of chronic obstructive pulmonary disease, or AECOPD; and BGS-649 for the treatment of hypogonadotropic hypogonadism ("HH") in obese men. Each of the Company's product candidates has generated positive clinical data for Mereo's target indication or in a related indication. The Company's strategy is to selectively acquire product candidates that have already received significant investment from pharmaceutical companies and that have substantial preclinical, clinical and manufacturing data packages. Since inception the Company has commenced large, randomized, placebo-controlled Phase 2 clinical trials for three of the product candidates and announced positive top-line results from its Phase 2 clinical trial of BCT-197 as an acute therapy for patients with AECOPD in December 2017 and positive top-line data from its Phase 2b dose-ranging study with BGS-649 for the treatment of HH. The Company intends to commence additional late-stage clinical trials in 2018.